Key result
Carvedilol and metoprolol did not improve the VE/VCO2 slope overall, but carvedilol was more effective than metoprolol in improving the slope in patients with baseline BNP >63 pg/ml (p<0.05).
Why the study?
Does carvedilol improve exercise ventilatory efficiency (VE/VCO2 slope) compared to metoprolol in patients with congestive heart failure?
RCT (n=57)
randomized
Does carvedilol improve exercise ventilatory efficiency (VE/VCO2 slope) compared to metoprolol in patients with congestive heart failure?
While neither beta-blocker improved exercise ventilatory efficiency in the overall mild heart failure cohort, carvedilol may offer superior improvement in VE/VCO2 slope compared to metoprolol in patients with more advanced disease (higher BNP).
Neither beta-blocker improves VE/VCO2 slope overall in mild HF; leaves open carvedilol advantage in higher-BNP patients.
BACKGROUND: The slope of the relationship between ventilation and carbon dioxide production (VE/VCO2 slope), obtained during symptom-limited ramp exercise testing, reflects exercise ventilatory efficiency. Importantly, the VE/VCO2 slope is related to prognosis in patients with congestive heart failure (CHF). The aim of the present study was to determine the relationship between the institution of beta-blockers, carvedilol or metoprolol, and the VE/VCO2 slope during exercise in patients with CHF. METHODS AND RESULTS: Fifty-seven patients with New York Heart Association functional class II or III with a radionuclide left ventricular ejection fraction (LVEF) of less than 40% received carvedilol or metoprolol in a randomized fashion. The VE/VCO2 slope, LVEF and plasma brain natriuretic peptide (BNP) concentration were determined before and after 16 weeks of treatment. LVEF improved (p<0.01), but the VE/VCO2 slope and BNP did not. A significant improvement in the VE/VCO2 slope was observed in patients with LVEF <29% or BNP >63 pg/ml (respective baseline median values) (p<0.05, p<0.05). In patients with BNP >63 pg/ml, the improvement effect on the VE/VCO2 slope with carvedilol was significantly greater than that with metoprolol (p<0.05) and a significant improvement in the VE/VCO2 slope was observed only in those who took carvedilol (p<0.01). CONCLUSIONS: The VE/VCO2 slope was not improved after beta-blocker therapy in any of the patients. However, it did improve in patients with a lower LVEF or higher BNP level at baseline, and carvedilol was more effective than metoprolol in improving the VE/VCO2 slope in patients with higher BNP levels at baseline.
No takes yet. Share an insight, caveat, or question.
Kataoka et al. (2008) conducted an RCT in congestive heart failure (CHF) (n=57). carvedilol vs. metoprolol was evaluated on VE/VCO2 slope. Carvedilol and metoprolol did not improve the VE/VCO2 slope overall, but carvedilol was more effective than metoprolol in improving the slope in patients with baseline BNP >63 pg/ml (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: